VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EMN 2018 | Refining MRD analysis in myeloma: the role of PET-CT and MRI

Measurable residual disease (MRD) can be determined using a variety of techniques. However, the majority of trials perform bone marrow MRD evaluation, while few are determining the effectiveness of PET-CT and MRI. Here, Elena Zamagni, MD, PhD, from the University of Bologna, Bologna, Italy, explains some of the complications regarding interpreting patient MRD and how incorporating these imaging techniques could help reduce this ambiguity. This interview took place at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter